Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study

被引：0

作者：

Danese, S. ^{[1
,2
]}

Abreu, M. T. ^{[3
]}

Wolf, D. C. ^{[4
]}

Canavan, J. B. ^{[5
]}

Jain, A. ^{[5
]}

Wu, H. ^{[5
]}

Petersen, A. ^{[5
]}

Charles, L. ^{[5
]}

Panaccione, R. ^{[6
]}

Afzali, A. ^{[7
]}

机构：

[1] IRCCS Osped San Raffaele, Milan, Italy

[2] Univ Vita Salute San Raffaele, Head Gastroenterol & Gastrointestinal Endoscopy U, Milan, Italy

[3] Univ Miami, Gastroenterol Div, Miller Sch Med, Miami, FL USA

[4] Atlanta Gastroenterol Associates LLC, IBD Res, Atlanta, GA USA

[5] Bristol Myers Squibb, Clin Res, Princeton, NJ USA

[6] Inflammatory Bowel Dis Clin, IBD Res, Edmonton, AB, Canada

[7] Univ Cincinnati, Gastroenterol, Coll Med, Cincinnati, OH USA

来源：

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

DOP37

引用

页码：I101 / I102

页数：3